Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
ÐǺ£ÆåÅÆ
NationalityDanish
BornSeptember, 1951
Anders Gersel Pedersen has more than 30 years’ board and management experience in publicly traded, international pharmaceutical and biotech companies. He has significant knowledge and expertise in discovery and development of the product pipeline from preclinical activities to post-launch marketing studies as well as solid business experience. Anders Gersel Pedersen furthermore has extensive experience with the global pharmaceutical market and has built comprehensive knowledge and insight in governance, including business conduct, and the development of ESG other sustainability related responsibilities from various leadership roles and as a board member. Anders Gersel Pedersen is former Executive Vice President of Research & Development of H. Lundbeck.
History
StatusNon-Independent
Elected ByGeneral Meeting
First Elected2003
Current Term Expires2026
Committee Positions
ChairCompensation
MemberScientificNominating & Corporate Governance
Current Board Positions
ChairAelis Farma S.A.S.
Deputy ChairBavarian Nordic A/S1
MemberHansa Biopharma AB2 Bond 2 Development 2 GP Limited
1. Member of Finance, Risk and Audit Committee, Member of Science, Technology & Investment Committee
2. Chair of Scientific Committee, Member of Remuneration Committee